SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: DRS/A
Document Type: DRS/A
Date Filed: 2025-12-12
Accession Number: 0001493152-25-027406
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315225027406/filename1.htm

Chunk 51 of 89
Word Count: 1493
Character Count: 9938

Document Content:

have obtained approval but are currently not commercially operating in order to preserve capital) and is in its pivotal trial in the United States. We also have ownership rights to Alginate, a hydrogel-based device treatment for HFrEF patients without anterior scarring. This device was CE-marked in Europe and had received an IDE in the U.S. (though the CE-mark has lapsed and utilizing the IDE would require a meeting with the FDA regarding a proposed plan). MANAGEMENT Executive Officers and Directors The following table sets forth information regarding our executive officers, directors and director nominees as of the date of this prospectus. Name Age Position David Richmond 53 Chairman, Co-Chief Executive Officer, and Chief Financial Officer Steven Chartier 57 President, Co-Chief Executive Officer, and Director Ori Ben-Yehuda 66 Chief Medical Officer Mark Ravich 72 Independent Director Nominee Rishi Puri 48 Independent Director Nominee William Abraham 66 Independent Director Nominee Executive Officers

David
Richmond has been our Chairman, President, Co-Chief Executive Officer, and Chief Financial Officer since January 2024. Prior
to that, from July 2019, Mr. Richmond was a board observer of our Board before being asked to become a full board member in August 2021.
Since 1994, Mr. Richmond has also been the founding partner and Chairman of Richmond Brothers, Inc. (“RBI”), an SEC registered
investment advisor. Mr. Richmond has been responsible for the strategic planning of RBI and its affiliates, led the creation of RBI private
funds, and sits as committee chairman for overall client asset allocation. RBI private funds specialize in (but are not limited to) biotech,
pharma, specialty pharma, and medical device companies. RBI private funds prefer to focus on disruptive companies developing their first
drug or device changing the paradigm in the area in which they operate.

Richmond earned his BA in Marketing from Michigan State University in 1994. He earned his Master of Science in Financial Services
(MSFS) as well as his CLU, ChFC, CAP designations from the American College. Mr. Richmond is a Certified Public Company Director through
the UCLA Anderson School of Management (2021).

Steven
Chartier has been our President, Co-Chief Executive Officer, and Director since Jan 15, 2025. With over 30 years of experience
in the medical device and biotechnology industries, Mr. Chartier has demonstrated leadership in both large organizations and startup
environments. Prior to his current role, from January 2024 to January 2025, he served as Vice President of Regulatory and Quality at
Conformal Medical, Inc., a company specializing in cardiovascular left atrial appendage devices. His previous tenure at BioVentrix, spanning
from December 2021 to December 2023, included serving as Chief Operating Officer. Mr. Chartier was Vice President of Clinical Operations
at Sirtex Medical from September 2020 to December 2021. Mr. Chartier has also held key positions at Cardiovascular Clinical Sciences
(2019-2020), Anika Therapeutics (2017-2019), and InfraReDx (2007-2015), where he developed expertise in clinical operations, regulatory
affairs, quality assurance, and manufacturing. Notably, at Anika Therapeutics, he was Vice President of Regulatory and Clinical Affairs,
overseeing global regulatory strategies and clinical development for the company’s orthobiologics and regenerative medicine pipeline.
Mr. Chartier began his career in clinical research and trial coordination at Dana-Farber Cancer Institute and Beth Israel Deaconess Medical
Center. Mr. Chartier earned a Bachelor of Arts in Psychology from Saint Anselm College in 1990 and obtained Regulatory Affairs Certification
from the Regulatory Affairs Professional Society in 2003.

Ori Ben-Yehuda has been our Chief Medical Officer since January 2024 and is a distinguished clinical cardiologist and
clinical trialist with over 25 years of experience in treating patients with coronary disease, myocardial infarction, and heart failure.
In addition to his role at BioVentrix, Dr. Ben-Yehuda is a Professor of Medicine at the University of California, San Diego (UCSD), where
he leads the Cardiovascular Outcomes Group at the Sulpizio Cardiovascular Institute. Dr. Ben-Yehuda also holds editorial positions as
Editor-in-Chief of Coronary Artery Disease and Deputy Editor of Structural Heart: The Journal of the Heart Team. Dr. Ben-Yehuda’s
previous roles include Executive Director of the Clinical Trials Center at the Cardiovascular Research Foundation and Vice President
of Cardiovascular Clinical Trials at Gilead Sciences. Dr. Ben-Yehuda has authored and co-authored over 200 peer-reviewed publications
and has been recognized with multiple awards, including Top Abstract at the TCT Conference in 2017 and the Sackler Faculty Prize for
Excellence for his MD thesis. Dr. Ben-Yehuda earned his medical degree from the Sackler School of Medicine at Tel Aviv University in
Israel and completed a cardiovascular medicine fellowship at UCSD.

Director
Nominees

Mark
H. Ravich will serve as a director following the consummation of this offering. Since June 2017, Mr. Ravich has been a director
of Rockwell Medical (Nasdaq: RMTI), a pharmaceutical company, and is currently a member of its audit committee. Mr. Ravich also currently
serves as president of Tri-Star Management, Inc., a commercial real estate management and syndication company that he co-founded
in 1998. From October 2010 through December 2022, Mr. Ravich served as a director of Dilon Technologies, Inc., a designer and manufacturer
of medical imaging solutions. In addition, from February 2019 to March 2023, Mr. Ravich previously served as a director of BioVentrix.
Previously, from February 2013 to 2018, Mr. Ravich served as a director of Orchids Paper Products Company, a national supplier of high-quality
consumer tissue products, as well as chairman of its governance committee and as a member of its audit committee. Orchids Paper Products
Company filed for Chapter 11 bankruptcy on April 1, 2019, in the U.S. Bankruptcy Court for the District of Delaware. From June 2004 to
2018, Mr. Ravich served as a director of MR Instruments, Inc., an independent designer and manufacturer of advanced MRI Radiofrequency
coils. From 1990 until its sale in 1998, Mr. Ravich served as the chief executive officer and a director of Universal International,
Inc., a wholesale retail company, where he also led its initial public offering. From 1978 to 1990, Mr. Ravich was a developer of commercial
real estate where he was involved with all aspects of development, finance, construction, marketing, leasing and management of various
commercial, industrial, office and multi-family real estate projects. Mr. Ravich began his career in 1975 as an account officer at Citibank
N.A., where he made real estate construction loans to national real estate developers. Mr. Ravich also is the chief manager of various
real estate entities. Mr. Ravich graduated Magna Cum Laude from the Wharton School of the University of Pennsylvania with a B.S. and
an M.B.A. degree with a major in finance. We believe that Mr. Ravich’s extensive board experience across the pharmaceutical, medical
device, and real estate sectors, combined with his financial expertise and leadership in both public and private companies qualifies
him to be a member of our board of directors.

Rishi
Puri, M.D., Ph.D., FRACP, FACC

Dr. Puri has been
a coronary and structural interventional cardiologist at the Cleveland Clinic since 2018. With his appointment he was also named
an Associate Professor of Medicine and Medical Director of the Angiography & IVUS Core Laboratory and has also served in such
capacity since 2018. Since July 2025, he has served as Chief Medical Director of T45 Labs, a Bay Area medical device incubator,
and since July 2018, he has served as Medical Director of the Atherosclerosis Imaging Core Laboratory. He has held the
post of Adjunct Professor at Swinburne University of Technology since 2024. Dr. Puri was Associate Professor (adjunct) at the Institute
for Intelligent Systems Research and Innovation at Deakin University from 2017 through April 2025.

He has published
over 450 original manuscripts in high-impact journals across a broad topic base including transcatheter structural heart
interventions for valvular heart disease and heart failure, atherosclerosis progression-regression and plaque imaging, and coronary
physiology/pharmacology. He is actively involved in developing novel device-based technologies in coronary, structural heart
disease, and interventional heart failure, and has co-founded and advises a range of medical start-up companies and larger
strategics.

Dr. Puri currently
serves as global co-principal investigator (“PI”) for the TRICAV-1 and TRICAV-2 FDA pivotal trials, a position
he has held since April 2022, and the ADVANCE-DCB first-in-man trial, which he has served as since September 2022. Since early 2025,
Dr. Puri has been national principal investigator for the ALLAY-HFrEF trial. He also serves on the global steering committees of
multiple other pivotal trials in the aortic, mitral and tricuspid valve therapy space.

Dr. Puri completed his
medical degree (MBBS) and a Ph.D. in medicine/cardiology at the University of Adelaide in 2001 and 2014, respectively, during
which time he also held an internship, residency, and a fellowship in internal medicine and cardiology at the Royal Adelaide Hospital.Dr.
Puri then completed subspecialty training in interventional and structural heart disease at the Québec Heart and Lung Institute
in Quebec City from 2014 to 2017, at the Rennes University Hospital during 2017, and was appointed visiting Senior Staff Cardiologist
at Royal Adelaide Hospital in 2017 and 2018, and at the Universitätsspital Zürich in 2018.He received his FRACP degree
from the Royal Australasian College of Physicians in 2008.